Prostate

• (101-21) A Phase 1 Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients with Advanced Solid Tumors
• (114-19) A Phase 1, open label, first-in-human study of TR1801-ADC, an antibody drug conjugate (ADC), in patients with select solid tumors expressing c-Met
• (114-20) Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone (ARROW)
• (115-16) Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer
• (178-18) A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
• (184-20) 2-(3-{1-CARBOXY-5-[(6-18F-FLUORO-PYRIDINE-3-CARBONYL)-AMINO]-PENTYL}-UREIDO)-PENTANEDIOIC ACID (PyL) in patients with high Risk and biochemically recurrent prostate cancer
• (187-19) A Phase 1/2 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer

• (221-19) Study of GNX102 in Patients With Advanced Solid Tumors

Certain clinical trials may not be listed on ClinicalTrials.gov. To learn more about these or other clinical trials, please call 949-764-5543 or contact us online.